Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

DurvalumabIntrahepatic CholangiocarcinomaGemcis

Interventions

DRUG

Durvalumab

1500mg intravenous injection for 21d cycle

PROCEDURE

Surgery

DRUG

Gemcitabine

gemcitabine 1000mg/m2, D1\&D8, 21d cycle.

DRUG

Cisplatin

cisplatin 25mg/m2, D1\&D8, 21d cycle.

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER